Restart Life Sciences Corp. (NMLSF) Stock Price & Analysis
Restart Life Sciences Corp. (NMLSF) — price $0.0633 (0.00%), as of the Nov 19, 2026 trading session; market cap $3.96M.
Educational signal · not a buy or sell recommendation · How to read this
Restart Life Sciences Corp. · NMLSF
Restart Life Sciences Corp. is a biotechnology company based in Vancouver, Canada, primarily focused on the research and development of psilocybin. The firm aims to create therapeutic treatments and diagnostic instruments specifically for neuroinflammatory conditions.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0633 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0101 – $0.1242 | |
| Market capitalisation | $3.96M | |
| Shares traded on the day | 10 |
Price & events
Other perspectives
Council score for Restart Life Sciences (NMLSF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 2, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Restart Life Sciences (NMLSF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Restart Life Sciences Corp. (NMLSF) is the company analyzed here. It is led by Steve Loutskou. In Q2 FY2026 it reported revenue of C$331,162 and net income of -C$1M. The market values it at $3.96M.
What do the latest results show for Restart Life Sciences (NMLSF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of C$331,162.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | C$331,162 | -C$1M | -C$0.02 (diluted) |
| Q1 FY2026 | C$134,899 | -C$326,982 | -C$0.01 (diluted) |
What are the financial strengths and risks for Restart Life Sciences (NMLSF)?
Short answer · as of
The distress and quality screens read Altman Z -42.13 · Piotroski F 5. Trailing ratios: ROA -89.9% · current ratio 1.85 · earnings yield -37.6% · free-cash-flow yield -21.0%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NMLSF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported NMLSF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About NMLSF
These answers are editorial: 1 of these 8 answers is drawn from the NMLSF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is NMLSF a good stock to buy?
Stock Expert AI does not rate NMLSF buy, sell or hold. Restart Life Sciences Corp. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the NMLSF stock price today?
The last price recorded for Restart Life Sciences Corp. (NMLSF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key challenges facing Restart Life Sciences Corp. in the biotechnology sector?
Restart Life Sciences Corp. faces several significant challenges inherent to the biotechnology sector, especially as an early-stage company. A primary challenge is the high risk and capital intensity of drug development, where clinical trial failures are common and can lead to substantial financial losses.
What are the key factors to evaluate for NMLSF?
Evaluate NMLSF on fundamentals, analyst consensus, and risk factors. Primary focus on psilocybin research and development for neuroinflammatory conditions, positioning the company in an emerging therapeutic area. Not financial advice.
How frequently does NMLSF data refresh on this page?
NMLSF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven NMLSF's recent stock price performance?
Restart Life Sciences Corp. (NMLSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Niche focus on psilocybin and neuroinflammatory conditions, addressing an area with unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NMLSF overvalued or undervalued right now?
Restart Life Sciences Corp. (NMLSF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NMLSF before investing?
Before investing in Restart Life Sciences Corp. (NMLSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 8 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com